Iovance Biotherapeutics, Inc.
Hedge Funds Holdings
Last updated:
Iovance Biotherapeutics, Inc.‘s stocks are currently a part of 237 hedge funds’ portfolios, which represents 100% of the total amount of its stocks outstanding. This makes up a total of 154.34M shares of Iovance Biotherapeutics, Inc.. Compared to the previous quarter, the number fell by -0.94% or -1.46M shares fewer. As for the holding position changes, 43.46% (103) of current hedge fund investors increased the number of shares held, 27% (64) of current holders sold a part of the shares held, and 15.61% (37) closed the holdings completely. 43 hedge funds are new holders of Iovance Biotherapeutics, Inc. stock in Q1 2022, it is 18.14% of total holders.
Hedge funds holding Iovance Biotherapeutics (Q2 2017 – Q1 2022)
| Q2 2017 | 83 |
|---|---|
| Q3 2017 | 86 |
| Q4 2017 | 86 |
| Q1 2018 | 121 |
| Q2 2018 | 124 |
| Q3 2018 | 129 |
| Q4 2018 | 135 |
| Q1 2019 | 149 |
| Q2 2019 | 162 |
| Q3 2019 | 166 |
| Q4 2019 | 192 |
| Q1 2020 | 215 |
| Q2 2020 | 251 |
| Q3 2020 | 243 |
| Q4 2020 | 261 |
| Q1 2021 | 243 |
| Q2 2021 | 227 |
| Q3 2021 | 236 |
| Q4 2021 | 237 |
| Q1 2022 | 237 |
Hedge funds changes in Iovance Biotherapeutics positions (Q2 2017 – Q1 2022)
| Q2 2017 | 83 | 0 | 0 | 0 | 0 |
|---|---|---|---|---|---|
| Q3 2017 | 16 | 36 | 19 | 13 | 2 |
| Q4 2017 | 13 | 33 | 24 | 13 | 3 |
| Q1 2018 | 43 | 52 | 18 | 7 | 1 |
| Q2 2018 | 23 | 53 | 34 | 18 | -4 |
| Q3 2018 | 25 | 47 | 31 | 21 | 5 |
| Q4 2018 | 31 | 66 | 29 | 25 | -16 |
| Q1 2019 | 31 | 36 | 49 | 16 | 17 |
| Q2 2019 | 45 | 53 | 40 | 29 | -5 |
| Q3 2019 | 27 | 62 | 55 | 23 | -1 |
| Q4 2019 | 43 | 74 | 60 | 12 | 3 |
| Q1 2020 | 52 | 73 | 69 | 25 | -4 |
| Q2 2020 | 71 | 93 | 64 | 34 | -11 |
| Q3 2020 | 43 | 83 | 90 | 50 | -23 |
| Q4 2020 | 57 | 82 | 96 | 38 | -12 |
| Q1 2021 | 39 | 99 | 74 | 56 | -25 |
| Q2 2021 | 46 | 100 | 54 | 60 | -33 |
| Q3 2021 | 33 | 88 | 88 | 23 | 4 |
| Q4 2021 | 37 | 94 | 81 | 35 | -10 |
| Q1 2022 | 43 | 103 | 64 | 37 | -10 |
Hedge funds changes in Iovance Biotherapeutics stock options (Q2 2017 – Q1 2022)
| Q2 2017 | 3,431,000 | 186,000 |
|---|---|---|
| Q3 2017 | 178,000 | 254,000 |
| Q4 2017 | 942,000 | 345,000 |
| Q1 2018 | 7,714,000 | 1,572,000 |
| Q2 2018 | 4,647,000 | 1,957,000 |
| Q3 2018 | 5,005,000 | 1,480,000 |
| Q4 2018 | 1,535,000 | 567,000 |
| Q1 2019 | 1,334,000 | 238,000 |
| Q2 2019 | 20,535,000 | 1,896,000 |
| Q3 2019 | 28,113,000 | 3,257,000 |
| Q4 2019 | 62,059,000 | 9,216,000 |
| Q1 2020 | 112,491,000 | 20,333,000 |
| Q2 2020 | 69,818,000 | 24,430,000 |
| Q3 2020 | 56,313,000 | 26,541,000 |
| Q4 2020 | 119,751,000 | 77,752,000 |
| Q1 2021 | 39,961,000 | 18,959,000 |
| Q2 2021 | 103,766,000 | 36,552,000 |
| Q3 2021 | 50,258,000 | 30,621,000 |
| Q4 2021 | 76,230,000 | 17,598,000 |
| Q1 2022 | 41,727,000 | 7,478,000 |